Enantioselective binding of carvedilol to human serum albumin and alpha‐1‐acid glycoprotein
Chirality · 2023
DOI: 10.1002/chir.23595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chirality, 2023. Verfasst von Camelia-Maria Toma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Medicine and Pharmacy, I.O.S.U.D., George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Ta…. Hauptthemen laut MEDLINE: Carvedilol, Orosomucoid, Serum Albumin, Human, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures.
Abstract (Originalsprache)
Carvedilol, a highly protein‐bound beta‐blocker, is used in therapy as a racemic mixture of its two enantiomers that exhibit different pharmacological activity. The aim of this study was to evaluate the stereoselective nature of its binding to the two major plasma proteins: albumin and alpha‐1‐acid glycoprotein. The determination of the plasma protein‐binding degree for carvedilol and its enantiomers was achieved using ultrafiltration for the separation of the free fraction, followed by LC‐MS/MS quantification, using two different developed and validated methods in terms of stationary phase: achiral C18 type and chiral ovomucoid type. Furthermore, molecular docking methods were applied in order to investigate and to better understand the mechanism of protein‐binding for S‐(−)‐ and R‐(+)‐carvedilol. A difference in the binding behavior of the two enantiomers to the plasma proteins was observed when taken individually, with R‐(+)‐carvedilol having a higher affinity for albumin and S‐(−)‐carvedilol for alpha‐1‐acid glycoprotein. However, in the case of the racemic mixture, the binding of the S enantiomer to alpha‐1‐acid glycoprotein seemed to be influenced by the presence of its antipode, although no such influence was observed in the case of albumin. The results raise the question of a binding competition between the two enantiomers for alpha‐1‐acid glycoprotein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School of Medicine and Pharmacy, I.O.S.U.D., George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.
- Department of Analytical Chemistry and Drug Analysis, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.
- Center of Advanced Medical and Pharmaceutical Research, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
ORCID-Profile: Camelia-Maria Toma
Förderung
- George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures
Zitieren
APA
Toma, C. M., Imre, S., Farczadi, L., Ion, V., & Marc, G. (2023). Enantioselective binding of carvedilol to human serum albumin and alpha‐1‐acid glycoprotein. Chirality. https://doi.org/10.1002/chir.23595
Vancouver
Toma CM, Imre S, Farczadi L, Ion V, Marc G. Enantioselective binding of carvedilol to human serum albumin and alpha‐1‐acid glycoprotein. Chirality. 2023. doi:10.1002/chir.23595
BibTeX
@article{Toma2023,
author = {Toma, Camelia-Maria and Imre, Silvia and Farczadi, Lenard and Ion, Valentin and Marc, Gabriel},
title = {Enantioselective binding of carvedilol to human serum albumin and alpha‐1‐acid glycoprotein},
journal = {Chirality},
year = {2023},
doi = {10.1002/chir.23595}
}
EUVIMED